ActHIB vaccine recalled in Japan

Thursday 10 March 2011 20:00 EST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Sanofi Pasteur and Daiichi Sankyo on Friday announced a recall of the ActHIB vaccine in Japan after an "unidentified substance" was found in two syringes.

Daiichi is the Japan marketer of the vaccine manufactured by Sanofi Pasteur, a wing of Paris-headquartered Sanofi-Aventis. The drug is used to prevent bacterial infections causing pneumonia and meningitis.

However, Daiichi told AFP most of the 1.3 million dose shipment had already been used and only a small percentage remained.

A Sanofi Pasteur official told AFP the company was checking how many vaccines had been used.

The official in Tokyo said that the doses "were manufactured on a production line dedicated to the Japanese market".

"They were delivered between September 2010 and late January 2011 but were produced about six months earlier," he added.

Japan's health ministry last week suspended the vaccine along with Pfizer's Prevenar, also used against bacteria that can cause meningitis and pneumonia.

The ministry is investigating the recent deaths of six infants who were administered either one or both of the treatments, or in combination with other drugs.

Both Pfizer and Sanofi-Aventis have vouched for the safety of their vaccines and said they are cooperating with the investigation in Japan.

mis-dwa/njc

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in